NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an ant
Personalized Medicine For Better Health
31, Oct 2022
23, Oct 2022
Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant pati
23, Oct 2022
Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference
23, Oct 2022
Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegal
26, May 2021
An exploratory study reported on May 23, 2021, in MedRxiv described changes in T-cell and antibody immunity after mRN
6, May 2021
In transplant recipients on chronic immunosuppression, COVID-19 infection is associated with impaired T-cell and anti
19, Mar 2021
On March 15, 2021, Boyarski et al.
28, Feb 2021
- On February 27, the FDA issued an Emergency Use Authorization for Johnson and Johnson’s non-mRNA vaccine.
5, Jan 2021
31, Dec 2020
Recurring symptoms lasting several months may require ongoing treatment in some patients who have experienced COVID-1
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA